



Evofem CEO Sandra Pelletier Calls for a “Ground-Up Reset” of Women’s Health at Fierce JPM Week 2026

Pelletier’s provocative keynote at Fierce JPM 2026 explores how moving beyond legacy models can drive progress in women’s health

SAN DIEGO, January 23, 2026 -- Women's health innovator Evofem Biosciences, Inc. ("Evofem") (OTCID: EVFM) announced today that CEO Sandra Pelletier’s fiery keynote address at Fierce JPM Week 2026 is now available for on-demand viewing.

“If men suffered from endometriosis, it would be solved by now,” said Pelletier. “Historically, clinical trials excluded women because our hormones have been deemed ‘too complicated’. These statements make people uncomfortable, but discomfort is long overdue.”

“Women’s health needs to be rewired and rebuilt – from the ground up. That’s why at Evofem our approach prioritizes transparency over persuasion, education over fear, and respect over control.”

In her keynote, Pelletier explored how long-standing, often archaic approaches to product development, education, and leadership have shaped — and hindered — progress in women’s health and shared how Evofem is taking a different path.

Fierce Pharma is providing free on-demand access to Pelletier’s keynote, “Rebuilding Women’s Health from the Ground Up,” making it available to those who were unable to attend live in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference last week.

You can watch the keynote on [Pelletier’s YouTube](#) page, or through the [Events page](#) on the Evofem investor website.

About Evofem Biosciences

[Evofem Biosciences, Inc.](#) is commercializing two FDA-approved sexual and reproductive health products:

- **PHEXX®** (lactic acid, citric acid, and potassium bitartrate) - the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexx.com to learn more and for important safety information.
- **SOLOSEC®** (secnidazole) 2 g oral granules - an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information.

PHEXX® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

Media Contact

media@evofem.com

Investor and Business Development Contact

Amy Raskopf

araskopf@evofem.com

(917) 673-5775